ESLA FY 2022 Earnings — Estrella Immunopharma, Inc. Revenue & Financial Results | Market Cap Arena

ESLAEstrella Immunopharma, Inc.

$53M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$2M

Net Income

-$996,104

EPS (Diluted)

$-0.17

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$1M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$10M

Total Liabilities

$3M

Stockholders' Equity

$7M

Cash & Equivalents

$40,802

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$2M	-$2M	+6.9%
Net Income	-$996,104	-$2M	+40.9%